Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511430 · ClinicalTrials.gov registry record
"SVEAT" Chest Pain Scoring System
A clinical trial, sponsored by University of Nevada, Reno.
- Completed
- Registry status
- 370
- Enrollment target
NCT03511430: Completed study, sponsored by University of Nevada, Reno.
NCT03511430 is a clinical trial that has completed, run by University of Nevada, Reno. The registered enrollment target is 370 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03511430 has completed, sponsored by University of Nevada, Reno.
- COMPLETED
- Registry status
- 370 participants
- Enrollment target
Study Summary
This is a prospective, observational study to assess the efficacy of the newly developed SVEAT scoring system in identifying low-risk patients who may be eligible for early discharge. Various elements of clinical information including Symptoms, Vascular history, EKG, Age and Troponin values will be checked and entered on the scoring form to calculate the SVEAT risk score. Additionally, HEART score and TIMI risk score will be calculated for the same subjects. The primary aim is to assess the positive and negative predictive values for the SVEAT index for cardiovascular events and compare it to the HEART and TIMI Scores.
Primary Outcome
The number of subjects diagnosed with MACE (Acute Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting, Significant stenosis with conservative therapy, Death)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2018-10-10 |
What the finished NCT03511430 record still lists
NCT03511430 is an observational study that tracks outcomes without assigning an intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03511430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03511430 about?
NCT03511430 is a clinical study titled ""SVEAT" Chest Pain Scoring System". This is a prospective, observational study to assess the efficacy of the newly developed SVEAT scoring system in identifying low-risk patients who may be eligible for early discharge. Various elements of clinical information including Symptoms, Vascular history, EKG, Age and Troponin values will be ...
What is the current status of trial NCT03511430?
This trial is currently completed. The enrollment target is 370 participants. The study started on 2017-05-01. Estimated completion is 2018-10-10.
Who is sponsoring clinical trial NCT03511430?
This trial is sponsored by University of Nevada, Reno, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI